TrialCancer cell2021
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial.
Lajos Pusztai et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
231 papers cite itlatest 60 shown
this paperpooled ittrialcites it